Growth levers activated
Granules India (GRAN IN) is a vertically integrated pharmaceutical manufacturer with capabilities across APIs, PFIs, and finished dosages, with strong presence in regulated markets, particularly the US. Over the past decade, GRAN has transitioned from a bulk API led model to a US-focused formulations platform, with rising exposure to complex and differentiated products. Backward integration, cost efficiency, and scale economics underpin GRAN’s competitive positioning, while increasing contribution from low-competition products is structurally improving the quality of the business. Remediation of regulatory issues at Gagillapur plant is likely in the near-term, in our assessment. Additional capacity commissioned at Genome Valley plant will also support growth. We project mid-high-teen topline growth with ~100bps EBITDA margin expansion for GRAN over the next two years. We initiate coverage with Buy and a TP of INR 775.
Strategic levers strengthening growth visibility: GRAN has evolved from a high-volume API manufacturer into a vertically integrated formulations player with growing exposure to regulated markets. While legacy APIs built scale and cost leadership, forward integration into PFIs and finished dosages has improved value capture and customer stickiness. The US formulation business will enhance margin visibility and strengthen overall business quality. The Senn & Ascelis acquisition adds peptide CDMO capabilities and exposure to high-growth segments such as GLP-1, enhancing diversification and earnings durability.
Capacity expansion and regulatory resolution to unlock growth: GRAN’s growth visibility is supported by capacity expansion, regulatory normalization, and portfolio upgradation. We expect remediation of regulatory issues at Gagillapur to restore approval momentum, removing a key launch bottleneck. The Genome Valley facility adds incremental capacity of ~10bn doses, with which accelerating ANDA commercialization, and expansion into controlled substances, CNS, and oncology will add to growth.
Earnings inflection underway: We see GRAN at the start of a structurally stronger earnings cycle. Lower remediation costs, better operating leverage, higher contribution from complex and differentiated formulations and turnaround in the recently acquired Senn & Ascelis subsidiary should help expand margins. We project ~15% revenue CAGR and ~17-18% EBITDA CAGR in FY26E-28E.
Improving cash flow and capital efficiency: With peak capex largely behind and utilization expected to rise, FCF should strengthen meaningfully from FY27. Integrated operations support better asset turns and ROIC, and declining leverage enhances balance sheet flexibility and opportunities for inorganic growth.
Initiate with BUY and a TP of INR 775: GRAN trades at 16.7x FY28E core EPS, adjusted for cash per share, at 10-20% discount to most generics pharma peers. We initiate coverage on GRAN with BUY rating and TP of INR 775 which is 24x FY28E core earnings plus cash per share. Delay in resolution of USFDA-warning letter and worsening of competitive scenario in the US generics market are key risks to our call.
